Page last updated: 2024-10-25

phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and Temporomandibular Disorders

phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide has been researched along with Temporomandibular Disorders in 1 studies

phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide: cyclic somatostatin octapeptide analog with high affinity & selectivity toward mu opioid receptors

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Macedo, CG1
Fanton, LE1
Fischer, L1
Tambeli, CH1

Other Studies

1 other study available for phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and Temporomandibular Disorders

ArticleYear
Coactivation of μ- and κ-Opioid Receptors May Mediate the Protective Effect of Testosterone on the Development of Temporomandibular Joint Nociception in Male Rats.
    Journal of oral & facial pain and headache, 2016,Winter, Volume: 30, Issue:1

    Topics: Animals; Brain Stem; Facial Pain; Formaldehyde; Male; Naloxone; Naltrexone; Narcotic Antagonists; No

2016